Seeking Alpha
  • Michael Bryant
    I have to agree with Cramer, Sarepta Therapeutics' (SRPT) orphan drug status could be a huge advantage. http://bit.lyPxXDwC__source=yahoo|headline|quote|video|&par=yahoo
    10/3/12
    Reply (5)
    • Michael Bryant: http://bit.ly/PxXDwC__source=yahoo|headline|quote|video|&par=yahoo
      10/3/12
    • TruffelPig: But Orphan Drug means very few patients. Doesn't it?
      10/3/12
    • anonymous#12: And a very steep price so bigger profits per treatment. Just look at JAZZ, QCOR what they have done with orphan drugs.
      10/3/12
    • Michael Bryant: Truffel: Yup, few patients, but you get federal help and a lot of exclusivity.
      10/3/12
    • TruffelPig: Thanks for clarification on this.
      10/3/12